Key Highlights
- Phase 3 X-TOLE2 trial met its primary endpoint at both azetukalner doses tested in adult focal epilepsy.
- The 25 mg arm cut monthly seizure frequency by 53.2%, versus 10.4% for placebo.
- A growing share of patients reached complete seizure freedom over the 12-week double-blind period.
- Full data is due at the European Epilepsy Congress on September 7, 2026, with an NDA filing planned for the third quarter.
A Late-Stage Readout for Focal Epilepsy
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is advancing azetukalner (XEN1101) through late-stage development for adult focal epilepsy, one of the most common forms of the seizure disorder. The company's X-TOLE2 Phase 3 study has already cleared its primary endpoint, and the full dataset is scheduled for presentation at the European Epilepsy Congress (EEC) on September 7, 2026.
Focal epilepsy, where seizures originate in a specific area of the brain, remains difficult to control for a meaningful share of patients despite a wide range of existing anticonvulsants. A new mechanism with a clean late-stage readout tends to draw close attention from both clinicians and regulators evaluating unmet need in the category.
What the Trial Showed
A late-breaking presentation at the American Academy of Neurology (AAN) meeting on April 20, 2026 reported that the 25 mg azetukalner dose reduced monthly seizure frequency by 53.2%, compared with 10.4% for placebo. The same presentation noted that the proportion of patients achieving complete, 100% seizure reduction continued to increase through the 12-week double-blind treatment period, a pattern that suggests a cumulative rather than a one-off treatment effect.
Separately, on March 9, 2026, Xenon (NASDAQ:XENE) confirmed that the Phase 3 trial met its primary endpoint across both dose groups studied, with the 25 mg arm again showing a -53.2% median percent change in monthly focal-onset seizure (FOS) frequency from baseline against -10.4% for placebo.
Regulatory Path and Timeline
With the primary endpoint met and safety data accumulated across the program, Xenon (NASDAQ:XENE) has indicated it plans to submit a New Drug Application (NDA) to the FDA in the third quarter of 2026. The EEC presentation on September 7 is expected to give physicians and investors their first look at the complete dataset underpinning that filing, including secondary endpoints and longer-term tolerability data not yet fully disclosed.
Market Reaction
Shares of Xenon (NASDAQ:XENE) traded at $61.93, down 2.92% intraday, against a market Capitalization of roughly $6 billion. The pullback comes ahead of the EEC presentation, a pattern not unusual for clinical-stage names heading into a binary data event, where positioning can shift regardless of the underlying trial trajectory.
What is azetukalner and what condition is it being developed for?
Azetukalner (XEN1101) is an investigational treatment being developed by Xenon Pharmaceuticals (NASDAQ:XENE) for adult focal epilepsy, evaluated in the Phase 3 X-TOLE2 program.
When will full Phase 3 data be presented?
Full Phase 3 results are scheduled for presentation at the European Epilepsy Congress (EEC) on September 7, 2026.
When does Xenon plan to file for FDA approval?
Xenon Pharmaceuticals (NASDAQ:XENE) has indicated it plans to submit a New Drug Application to the FDA in the third quarter of 2026.






Please wait processing your request...